Mablink was founded in 2018 following its discovery of the disruptive PSARlink™ hydrophilic ADC technology, which addresses most of the technological barriers currently slowing down the translation of ADC from the laboratory bench to the patients. We apply the PSARlink™ technology to our own pipeline of ADC but we also want other ADC developers to take advantage of PSARlink™ for their own programs.

We are therefore welcoming partnering inquiries so that, eventually, more patients can benefit from new and better treatments.